These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 26390167)

  • 1. Challenges and opportunities of allogeneic donor-derived CAR T cells.
    Yang Y; Jacoby E; Fry TJ
    Curr Opin Hematol; 2015 Nov; 22(6):509-515. PubMed ID: 26390167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential alternatives to αβ-T cells to prevent graft-versus-host disease (GvHD) in allogeneic chimeric antigen receptor (CAR)-based cancer immunotherapy: A comprehensive review.
    Tang C; Zhang Y
    Pathol Res Pract; 2024 Oct; 262():155518. PubMed ID: 39146830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 'Off-the-shelf' allogeneic CAR T cells: development and challenges.
    Depil S; Duchateau P; Grupp SA; Mufti G; Poirot L
    Nat Rev Drug Discov; 2020 Mar; 19(3):185-199. PubMed ID: 31900462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity.
    Ghosh A; Smith M; James SE; Davila ML; Velardi E; Argyropoulos KV; Gunset G; Perna F; Kreines FM; Levy ER; Lieberman S; Jay HV; Tuckett AZ; Zakrzewski JL; Tan L; Young LF; Takvorian K; Dudakov JA; Jenq RR; Hanash AM; Motta AC; Murphy GF; Liu C; Schietinger A; Sadelain M; van den Brink MR
    Nat Med; 2017 Feb; 23(2):242-249. PubMed ID: 28067900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.
    Marcus A; Eshhar Z
    Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Off-the-Shelf Allogeneic T Cell Therapies for Cancer: Opportunities and Challenges Using Naturally Occurring "Universal" Donor T Cells.
    Perez C; Gruber I; Arber C
    Front Immunol; 2020; 11():583716. PubMed ID: 33262761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic "Off-the-Shelf" CAR T cells: Challenges and advances.
    Chen S; van den Brink MRM
    Best Pract Res Clin Haematol; 2024 Sep; 37(3):101566. PubMed ID: 39396256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor-derived CD19 chimeric antigen receptor T cells.
    Singh N; Barrett DM
    Curr Opin Hematol; 2015 Nov; 22(6):503-8. PubMed ID: 26457962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donor-derived CD19-targeted T cells in allogeneic transplants.
    Magnani CF; Biondi A; Biagi E
    Curr Opin Hematol; 2015 Nov; 22(6):497-502. PubMed ID: 26390165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paving the way towards universal treatment with allogenic T cells.
    Townsend MH; Bennion K; Robison RA; O'Neill KL
    Immunol Res; 2020 Feb; 68(1):63-70. PubMed ID: 32096010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells.
    MacLeod DT; Antony J; Martin AJ; Moser RJ; Hekele A; Wetzel KJ; Brown AE; Triggiano MA; Hux JA; Pham CD; Bartsevich VV; Turner CA; Lape J; Kirkland S; Beard CW; Smith J; Hirsch ML; Nicholson MG; Jantz D; McCreedy B
    Mol Ther; 2017 Apr; 25(4):949-961. PubMed ID: 28237835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of allogeneic CAR T-cells].
    Alcazer V; Depil S
    Bull Cancer; 2021 Oct; 108(10S):S73-S80. PubMed ID: 34920810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition.
    Ren J; Liu X; Fang C; Jiang S; June CH; Zhao Y
    Clin Cancer Res; 2017 May; 23(9):2255-2266. PubMed ID: 27815355
    [No Abstract]   [Full Text] [Related]  

  • 15. Paving the Way Towards Universal Chimeric Antigen Receptor Therapy in Cancer Treatment: Current Landscape and Progress.
    Zhang Y; Li P; Fang H; Wang G; Zeng X
    Front Immunol; 2020; 11():604915. PubMed ID: 33362790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Off the shelf T cell therapies for hematologic malignancies.
    McCreedy BJ; Senyukov VV; Nguyen KT
    Best Pract Res Clin Haematol; 2018 Jun; 31(2):166-175. PubMed ID: 29909917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors.
    Torikai H; Cooper LJ
    Mol Ther; 2016 Aug; 24(7):1178-86. PubMed ID: 27203439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy.
    Lv Z; Luo F; Chu Y
    Front Immunol; 2023; 14():1199145. PubMed ID: 37554322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR NK-92 cell-mediated depletion of residual TCR+ cells for ultrapure allogeneic TCR-deleted CAR T-cell products.
    Kath J; Du W; Martini S; Elsallab M; Franke C; Hartmann L; Drosdek V; Glaser V; Stein M; Schmueck-Henneresse M; Reinke P; Volk HD; Abou-El-Enein M; Wagner DL
    Blood Adv; 2023 Aug; 7(15):4124-4134. PubMed ID: 37196643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.